

Table SIII. Evidence table

First author (Ref), year	Design	Dosage	Outcome measures	Date of evaluation (licensed dose)	Results (mean)
Adalimumab					
Ryan (12), 2009 (n=39 ^a)	Retrospect	Adalimumab 80 mg (W 0) followed by 40 mg once W (from W1) SC or adalimumab 40 mg EOW (from W1) SC. According to the response the dose interval was increased or decreased.	PASI75 Monotherapy PASI75 combination therapy	W 16 W 24 W 48 W 72 W 16 W24 W48 W72 W 12	PASI75: 38% PASI75: 62% PASI75: 69% PASI75: 71% PASI75: 56% PASI75: 50% PASI75: 80% PASI75: 67% PASI50: 70%
van Lümig (13), 2010 (n=30 ^a)	Prosp. ^b	Adalimumab 80 mg (W0) followed by 40 mg EOW (from W1–12) SC. From W12–48, according to the response the dose interval was maintained, increased or decreased. (Adalimumab 40 mg EOW or 40 mg every 10 days or 40 mg once W.	PASI50 PASI75 PASI90	Comparing with original PASI (licensed dose) W 24 Comparing with original PASI W 48 Comparing with original PASI W 12 Comparing with course PASI (licensed dose) W 24 Comparing with course PASI W 48 Comparing with course PASI W 12 Comparing with course PASI W 24 Comparing with course PASI W 48 Comparing with course PASI W 16 (licensed dose) W 24 W 52	PASI75: 27% PASI90: 10% PASI50: 61% PASI75: 36% PASI90: 7% PASI50: 77% PASI75: 54% PASI90: 15% PASI50: 30% PASI75: 13% PASI90: 13% PASI50: 50% PASI75: 7% PASI90: 0% PASI50: 54% PASI75: 23% PASI90: 15% PASI50: 84% PASI75: 64% PASI90: 36% PASI50: 77% PASI75: 65% PASI90: 42% PASI50: 56% PASI75: 48% PASI90: 41% PASI50: 90% PASI75: 68% PASI90: 42% PASI50: 95% PASI75: 82% PASI90: 56% PASI75: 89% PASI90: 75% PASI50: 100% PASI75: 88% PASI90: 75% PASI75: 64% PASI90: 49% PASI75: 67% PASI90: 60% PASI75: 76% PASI90: 70% PASI75: 83% PASI90: 71% PASI50: 65% PASI75: 35% PASI90: 11% PASI100: 0% PASI50: 69% PASI75: 45% PASI90: 17% PASI100: 6%
Warren (14), 2010 (n=46 ^a)	Retrospect	Adalimumab 80 mg (W 0) followed by 40 mg EOW (from W1) SC. According to the response the dose was increased to 40 mg weekly the first 4 months.	PASI50 PASI75 PASI90	W 16 (licensed dose) W 24 W 52	PASI50: 84% PASI75: 64% PASI90: 36% PASI50: 77% PASI75: 65% PASI90: 42% PASI50: 56% PASI75: 48% PASI90: 41%
Fotiadou (15), 2012 (n=52 ^a)	Retrospect	Adalimumab 80 mg (W 0) followed by 40 mg EOW (from W1) SC. According to the response the dose interval was increased or decreased	PASI50 PASI75 PASI90	W 16 W 24 W 52 W 72	PASI50: 90% PASI75: 68% PASI90: 42% PASI50: 95% PASI75: 82% PASI90: 56% PASI75: 89% PASI90: 75% PASI50: 100% PASI75: 88% PASI90: 75%
López-Ferrer (16), 2013 (n=119 ^a)	Retrospect	Adalimumab 80 mg (W 0) followed by 40 mg EOW (From W1) SC.	PASI75 PASI90	W 16 W 24 W 52 W 104	PASI75: 64% PASI90: 49% PASI75: 67% PASI90: 60% PASI75: 76% PASI90: 70% PASI75: 83% PASI90: 71%
van Lümig (17), 2013 (n=85 ^a)	Prosp.	Adalimumab 80 mg (W 0) followed by 40 mg EOW (from W1) SC. According to the response the dose interval was decreased.	PASI50 PASI75 PASI90 PASI100	W 12 Comparing with original PASI W 24 Comparing with original PASI	PASI50: 65% PASI75: 35% PASI90: 11% PASI100: 0% PASI50: 69% PASI75: 45% PASI90: 17% PASI100: 6%

			W 48	PASI50: 83%
			Comparing with original PASI	PASI75: 57%
				PASI90: 21%
				PASI100: 4%
			W 96	PASI50: 94%
			Comparing with original PASI	PASI75: 44%
				PASI90: 22%
				PASI100: 0%
			W 132	PASI50: 83%
			Comparing with original PASI	PASI75: 50%
				PASI90: 0%
				PASI100: 0%
			W 12	PASI50: 46%
			Comparing with course PASI	PASI75: 27%
				PASI90: 8%
				PASI100: 0%
			W 24	PASI50: 56%
			Comparing with course PASI	PASI75: 31%
				PASI90: 11%
				PASI100: 6%
			W 48	PASI50: 72%
			Comparing with course PASI	PASI75: 38%
				PASI90: 15%
				PASI100: 4%
			W 96	PASI50: 72%
			Comparing with course PASI	PASI75: 44%
				PASI90: 22%
				PASI100: 0%
			W 132	PASI50: 50%
			Comparing with course PASI	PASI75: 50%
				PASI90: 0%
				PASI100: 0%
Menting (18), 2014 (n=90 TE ^a)	Prosp.	Adalimumab 80 mg (W 0) followed by 40 mg EOW (from W1) SC or 40 mg every 10 days or 40 mg once W.	PASI75 Naive	W 12
			PASI90	W 52
			PASI75 Non-naive	W 12
			PASI90	W 12
				W 52
				PASI90: 8%
Etanercept				
de Groot (19), 2006 (n=50 ^a)	Retrospect.	Etanercept 50 mg BIW SC (W0–12).	PASI50	W 12
			PASI75	(licensed dose)
			PASI90	PASI75: 22.6%
			MPD	PASI90: 6.5%
			MBSAD	MPD: 57.5%
		Etanercept 25 mg BIW SC (W0–12).	PASI50	W 12
			PASI75	MBSAD: 62.3%
			PASI90	PASI50: 85.7%
			MPD	PASI75: 21.4%
			MBSAD	PASI90: 7.1%
				MPD: 60%
Berends (20), 2007 (n=45 ^a)	Prosp.	Etanercept 50 mg BIW SC (W0–12) followed by 25 mg BIW (W12–24).	PASI50	W 12 (licensed dose)
			PASI75	PASI50: 82%
				PASI75: 39%
				W 18 (licensed dose)
				PASI50: 88%
				PASI75: 47%
				W 24 (licensed dose)
				PASI50: 71%
				PASI75: 50%
		25 mg BIW SC (W0–24).	PASI50	W 12
			PASI75	PASI50: 71%
				PASI75: 24%
				W 18
				PASI50: 79%
				PASI75: 64%
				W 24
				PASI50: 79%
				PASI75: 57%
Barrera (21), 2008 (n=66)	Retrospect.	Etanercept 50 mg BIW SC (W0 – 12) followed by 25 mg BIW (W12–24) or 25 mg BIW (W0–24). Thereafter one of these treatments by losing 50% of the PASI. Three cycles of 24W.	PASI50	Cycle 1
			PASI75	W 12 (licensed dose)
			PASI90	PASI50: 65.5%
			MPD	PASI75: 36.1%
				PASI90: 21.3%
				Cycle 1
				W 24
				PASI50: 91.3%
				PASI75: 76.1%
				PASI90: 41.3%
				MPD: 78.1%

				Cycle 2	PASI50: 72.4%
				W 12	PASI75: 31%
					PASI90: 10.3%
				Cycle 2	PASI50: 94.7%
				W 24	PASI75: 63.2%
					PASI90: 31.6%
					MPD: 66.9%
				Cycle 3	PASI50: 60%
				W 12	PASI75: 33.3%
					PASI90: 20%
				Cycle 3	PASI50: 85.7%
				W 24	PASI75: 42.9%
					PASI90: 28.6%
					MPD: 76%
Driessen (22), 2008 (n=80 ^a)	Prosp.	Etanercept 50 mg BIW SC (W0–12) followed by 25 mg BIW (W12–24). According to the response the dose of 25 mg BIW was temporary increased.	PASI50 PASI75 PASI90 MPD	W 12 (licensed dose)	PASI50: 66%
		Etanercept 25 mg BIW SC (W0–24). According to the response the dose was temporary increased.	PASI50 PASI75 PASI90 MPD	W 24 (licensed dose) W 12	PASI75: 20%
					PASI90: 8%
					MPD: 59%
					PASI50: 68%
					PASI75: 21%
					PASI90: 5%
				W 24	MPD: 60%
Gisoni (40), 2008 (n=58)	Retrospect.	Etanercept 25 mg BIW SC.	MPD	W 24	MPD: 74.5%
Antoniou (23), 2009 (n=77 ^a)	Retrospect.	Etanercept 50 mg BIW SC (W0–12) followed by 25 mg BIW (W12–48). According to the response the dose was increased to 50 mg BIW.	PASI50 PASI75	W 24 W 48	PASI50: 79%
					PASI75: 53%
					PASI50: 81%
					PASI75: 49%
Driessen (24), 2009 (n=90 ^a)	Prosp.	Etanercept 50 mg BIW SC (W0–12) followed by 25 mg BIW (W12–24) or Etanercept 25 mg BIW SC (W0–W24). According to the response the dose was temporary increased to 50 mg BIW.	PASI50 PASI75 PASI90 MPD	W 24	PASI50: 69%
					PASI75: 39%
					PASI90: 18%
					MPD: 59.7%
Jiménez-Puya (25), 2009 (n=58)	Retrospect.	Etanercept 50 mg BIW SC or 25 mg BIW SC.	PASI50 PASI75 PASI90 MBSAD	W 8 W 16	PASI50: 77.6%
					PASI75: 41.4%
					PASI90: 6.9%
				W 16	PASI50: 86.8%
					PASI75: 66%
					PASI90: 37.7%
				W 24	PASI50: 97.5%
					PASI75: 85%
					PASI90: 57.5%
				W 32	PASI50: 100%
					PASI75: 80.8%
					PASI90: 57.7%
				W 40	PASI50: 94.7%
					PASI75: 84.2%
					PASI90: 52.6%
				48W	PASI50: 100%
					PASI75: 92.3%
					PASI90: 69.2%
					MBSAD: 85%
Mazzotta (26), 2009 (n=234)	Prosp. ^c	Etanercept 50 mg BIW SC (W0–12) followed by 25 mg BIW (W12–24)	PASI50 PASI75 MPD (psoriasis)	W 12 (licensed dose)	PASI50: 77.9%
				W 24 (licensed dose)	PASI75: 41%
					MPD: 67.7%
					PASI50: 85.7%
					PASI75: 73.2%
					MPD: 81%
				W 12 (licensed dose)	PASI50: 64 %
					PASI75: 43%
					MPD: 66.7%
				W 24 (licensed dose)	PASI50: 79.8%
					PASI75: 61.8%
					MPD: 80.5%
Warren (27), 2009 (n=70 ^a)	Retrospect.	Etanercept 25 mg BIW SC. According to the response the dose was increased to 50 mg BIW.	PASI50 PASI75 PASI90 MPD	W 12	PASI50: 67%
					PASI75: 35%
					PASI90: 7%
					MPD: 55%

				W 24	PASI50: 67% PASI75: 41% PASI90: 6% MPD: 59% PASI75: 57%
Antoniou (28), 2010 (n=35 ^a) van Lümig (13), 2010 (n=30 ^a)	Retros ^d Prosp.	Etanercept 50 mg BIW SC (W0–12) followed by 25 mg BIW (W12–24). Etanercept 50 mg BIW SC or 25 mg BIW SC (W0 – 12). Thereafter dosage according to physician.	PASI75 PASI50 PASI75 PASI90	W 24 (licensed dose) W 12 W 24 W 48	PASI50: 60% PASI75: 13% PASI90: 3.3% PASI50: 58% PASI75: 19% PASI90: 3.3% PASI50: 79% PASI75: 25%
Zaragoza (29), 2010 (n=43)	Retros ^c	Etanercept 50 mg BIW SC (W0–12) or 25 mg BIW SC (W0–12) followed by 25 mg BIW SC (W12–24). According to the response the dose was increased or decreased.	PASI50 PASI75 MPD	W 24 W 48 W 72 W 96 W 120 W 144	PASI50: 81.4% PASI75: 60.5% MPD: 73.8% PASI50: 90.5% PASI75: 71.4% MPD: 79.6% MPD: 81.3% MPD: 38.2% MPD: 87.6% MPD: 88.4%
Antoniou (30), 2011 (n=118 ^a)	Retros ^p	Etanercept 50 mg BIW SC (W0–12) followed by 50 mg once W (from W 12).	PASI50 PASI75	W 12 (licensed dose) W 24 (licensed dose) W 48 (licensed dose) W 72 (licensed dose) W 12 (licensed dose)	PASI50: 59% PASI75: 25% PASI50: 81% PASI75: 47% PASI50: 82% PASI75: 54% PASI50: 87% PASI75: 52% PASI50: 82% PASI75: 54.1%
Esposito (31), 2012 (n=61)	Retros ^c	Psoriasis patients with psoriatic arthritis: Etanercept 50 mg BIW SC. Patients with only psoriasis: Etanercept 50 mg BIW, followed by 25 mg BIW SC.	PASI50 PASI75 MPD	W 24 W 52 W 104 W 156	MPD: 73.3% PASI50: 90.2% PASI75: 78.7% MPD: 85.9% PASI50: 90.2% PASI75: 83.6% MPD: 87.9% PASI50: 91.8% PASI75: 86.9% MPD: 88.4% PASI50: 91.8% PASI75: 83.6% MPD: 86.9%
van Lümig (32), 2012 (n=152 ^a) (n=158 TE)	Prosp.	Etanercept 50 mg BIW SC or 25 mg BIW SC (W0–12). Thereafter dosage according to the physician.	PASI50 PASI75 PASI90	W 12 W 24 W 48 W 108 W 156 W 204 W 264	PASI50: 65.6% PASI75: 23.6% PASI90: 5.1% PASI50: 69.7% PASI75: 38.1% PASI90: 14.9% PASI75: 36.6% PASI75: 40.8% PASI75: 50% PASI75: 59.4% PASI75: 60%
Puig (33), 2012 (n=444 ^a)	Prosp.	Etanercept 50 mg BIW SC (W0 –12) or 50 mg once W or 25 mg BIW (W0–12). After 12 W patients reaching a PASI50 could continue treatment. After 6 months the decision was made to treat patients continuously or intermittently.	PASI50 PASI75 PASI90 MPD MBSAD MPhGAD	W 12 Overall W 12 Continuous regimen W 12 Intermittent regimen	PASI50: 88.4% PASI75: 63.9% PASI90: 37.8% MPD: 69.6% MBSAD: 66.4% MPhGAD: 62.5% PASI75: 63% PASI90: 34.8% PASI75: 64% PASI90: 38.4%

			PASI75	W 12	PASI75: 38%
			PASI90		PASI90: 12%
			Non-naive	W 52	PASI90: 14%
Ustekinumab					
Clemmensen (37), 2011 (n=71)	Prosp.	Ustekinumab 45 or 90 mg (W 0, 4, and every 12 W). ^e	PASI75	W 16 (licensed dose)	PASI75: 80%
Laws (38), 2012 (n=129 ^a)	Retrosop.	Ustekinumab 45 or 90 mg (W 0, 4 and every 12 W). ^e	PASI50 PASI75 PASI90	W 16 (licensed dose) W 24 (licensed dose) W 48 (licensed dose)	PASI50: 82.7% PASI75: 63% PASI90: 29.1% PASI75: 66.7% PASI75: 65.5%
Ruiz Salas (39), 2012 (n=36 ^a)	Retrosop.	Ustekinumab 45 mg (W 0, 4 and every 8–12 W). ^e	PASI50 PASI75 PASI90 MPD	W 12 W 24 W 36	PASI50: 89.6% PASI75: 79.3% PASI90: 65.5% PR: 80.7% PASI50: 89.6% PASI75: 79.3% PASI90: 75.9% MPD: 80.9% PASI50: 89.6% PASI75: 89.6% PASI90: 75.9% MPD: 89.3%
		Ustekinumab 90 mg (W 0, 4 and every 8–12 W).	PASI50 PASI75 PASI90 MPD	W 12 W 24 W 36	PASI50: 85.7% PASI75: 57.1% PASI90: 28.5% MPD: 75.6% PASI50: 57.1% PASI75: 28.5% PASI90: 14.2% MPD: 48.2% PASI50: 85.7% PASI75: 71.4% PASI90: 54.1% MPD: 80%
		Ustekinumab both groups [45 and 90 mg] (W 0, 4 and every 8–12 W).	PASI50 PASI75 PASI90 MPD	W 12 W 24 W 36	PASI50: 91.7% PASI75: 75% PASI90: 58.3% MPD: 79.5% PASI50: 83.3% PASI75: 69.4% PASI90: 63.9% MPD: 71.9% PASI50: 88.8% PASI75: 71.4% PASI90: 57.1% MPD: 86.8%
Gisoni (36), 2013 (n=79)	Prosp.	Ustekinumab 45 or 90 mg (W 0, 4 and every 12 W). Dosing is weight dependent. Individuals weight (≤100 kg= ustekinumab 45mg; >100kg= 90 mg).	PASI50 PASI75 MPD	W 4 (licensed dose) W 28 (licensed dose)	PASI75: 28% MPD: 82% PASI50: 82% PASI75: 58% MPD: 60%
Acitretin					
Piaserico (42), 2014 (n=62)	Retrosop.	Acitretin mean 0.38 mg/kg/day.	PASI75	W 12	PASI75: 27%
Fumarates					
Carboni (43), 2004 (n=40)	Prosp.	Fumarates 30–360 mg/day. By remission doses were gradually reduced.	MPD	W 4 W 12 W 24	MPD: 39.6% MPD: 63% MPD: 80%
Inzinger (44), 2013 (n=272)	Retrosop.	Fumarates 30–720 mg/day.	PASI50 PASI75 PASI90 PASI100	W 12 W 24	PASI50: 76% PASI75: 47% PASI90: 9% PASI100: 1% PASI50: 82% PASI75: 63% PASI90: 27% PASI100: 5%

				W 48	PASI50: 90% PASI75: 76% PASI90: 34% PASI100: 12%
Cyclosporine					
Piaserico (42), 2014 (n=36)	Retrospective	Cyclosporine mean 3.5 mg/kg/day.	PASI75	W 12	PASI75: 46%
Methotrexate					
Gisoni (40), 2008 (n=43)	Retrospective	Methotrexate 15 mg/week IM.	MPD	W 24	MPD: 47.6%
Inzinger (44), 2013 (n=72)	Retrospective	Methotrexate 10 mg/week SC increased to 20 mg/week SC.	PASI50 PASI75 PASI90 PASI100	W12 W 24 W 48	PASI50: 67% PASI75: 40% PASI90: 12% PASI100: 10% PASI50: 76% PASI75: 62% PASI90: 28% PASI100: 10% PASI50: 87.5% PASI75: 81% PASI90: 44% PASI100: 19%
Piaserico (42), 2014 (n=74)	Retrospective	Methotrexate mean 11.7 mg/week.	PASI75	W 12	PASI75: 49%

^aAdditional conventional systemic therapies. ^bPatient switched from etanercept. ^cPatients with psoriasis with or without psoriatic arthritis. ^dPatients switching from efalizumab. ^eDosing is weight dependent. Individuals weight (≤ 100 kg= ustekinumab 45 mg; >100 kg= 90 mg).

Retrospective: retrospective; Prospective: prospective; BIW: biweekly; BSA: body surface area; MBSAD: mean BSA decrease; EOW: every other week; IM: intramuscular; IV: intravenous; PASI: Psoriasis Area and Severity Index; MPD: mean PASI decrease; PhGA: Physician Global Assessment; MPhGAD: mean PhGA decrease; SC: subcutaneous; TE: treatment episode.